

33. (New) The pharmaceutical composition according to claim 29, wherein the said nicotinic receptor agonist is an $\alpha 7$ -nicotinic receptor agonist.
34. (New) A method for the treatment of a condition associated with reduced nicotine transmission, by administering to a patient in need of such treatment, a medically effective amount of a positive modulator of a nicotinic receptor agonist, said positive modulator having the capability to increase the efficacy of the said nicotinic receptor agonist.
35. (New) The method according to claim 34, wherein the said positive modulator is administered together with a nicotinic receptor agonist.
36. (New) The method according to claim 34, wherein the said positive modulator is 5-hydroxyindole.
37. (New) The method according to claim 35, wherein the said positive modulator is 5-hydroxyindole.
38. (New) The method according to claim 34, wherein the said nicotinic receptor agonist is an $\alpha 7$ -nicotinic receptor agonist.
39. (New) The method according to claim 35, wherein the said nicotinic receptor agonist is an $\alpha 7$ -nicotinic receptor agonist.
40. (New) The method according to claim 36, wherein the said nicotinic receptor agonist is an $\alpha 7$ -nicotinic receptor agonist.
41. (New) The method according to claim 34, for the treatment of Alzheimer's disease, Attention Deficit Hyperactivity Disorder, schizophrenia, anxiety or nicotine addiction.
42. (New) The method according to claim 35, for the treatment of Alzheimer's disease, Attention Deficit Hyperactivity Disorder, schizophrenia, anxiety or nicotine addiction.

43. (New) The method according to claim 36, for the treatment of Alzheimer's disease, Attention Deficit Hyperactivity Disorder, schizophrenia, anxiety or nicotine addiction.
44. (New) The method according to claim 38, for the treatment of Alzheimer's disease, Attention Deficit Hyperactivity Disorder, schizophrenia, anxiety or nicotine addiction.
45. (New) The method according to claim 34 for the treatment of Alzheimer's disease.
46. (New) The method according to claim 35 for the treatment of Alzheimer's disease.
47. (New) The method according to claim 36 for the treatment of Alzheimer's disease.
48. (New) The method according to claim 38 for the treatment of Alzheimer's disease.
49. (New) The method according to claim 34 for the treatment of Attention Deficit Hyperactivity Disorder.
50. (New) The method according to claim 35 for the treatment of Attention Deficit Hyperactivity Disorder.
51. (New) The method according to claim 36 for the treatment of Attention Deficit Hyperactivity Disorder.
52. (New) The method according to claim 38 for the treatment of Attention Deficit Hyperactivity Disorder.
53. (New) The method according to claim 34 for the treatment of schizophrenia.
54. (New) The method according to claim 35 for the treatment of schizophrenia.
55. (New) The method according to claim 36 for the treatment of schizophrenia.